Day 3 Program

Poster Session 3

Day 3: December 10, 2026

12:30 PM–2:00 PM CST

Exhibit Hall

Session Details

P3-1-01

A large scale, real-world data analysis evaluating a machine learning approach to distinguish multiple primary cancers from clinical relapse in breast cancer patients

Ana E Lohmann, Western University, London, ON, Canada

P3-1-02

Transpara AI Score dynamics could serve as imaging biomarker for distant recurrence beyond pCR in breast cancer patients with soft tissue lesions

Elia Prades Sagarra, ScreenPoint Medical B.V., Nijmegen, Netherlands

P3-1-03

Recurrence prediction in triple negative breast cancer (TNBC) patients using visual language foundation model (VLM)

Sunil S Badve, Winship Cancer Institute, Emory University, Atlanta, GA

P3-1-04

Cost-effectiveness of artificial intelligence-assisted risk stratification in early breast cancers in Sweden – a modelling study

Johan Hartman, Karolinska Institutet, Stockholm, Sweden

P3-1-05

IMPAiCT Ki-67: Effect on pathologist scoring concordance, speed and confidence with AI-assisted scoring in breast cancer patients

Alastair Ironside, NHS Lothian, Edinburgh, United Kingdom

P3-1-06

Prospective source-blinded comparison of recommendations made by artificial intelligence and experts for complex breast cancer cases

Mohammad Jahanzeb, Florida Atlantic University Schmidt College of Medicine, Boca Raton, FL

P3-1-07

A multi-magnification digital pathology foundation model trained on whole slide images for prognostication of distant recurrence in a registry of more than half a million breast cancer patients

Rick Baehner, Abbott Laboratories, Madison, WI

P3-1-08

Assessing quality of FFPE based RNA sequencing data: lessons from the PALLAS study

Sebastian Vosberg, Medical University of Graz, Graz, Austria

P3-1-09

Concordance and Survival Implications of Large Language Model (LLM) Versus Physician Adjuvant Chemotherapy (CT) Recommendations in Early-Stage Breast Cancer

Amy Schechter, University of Chicago, Chicago, IL

P3-1-10

Multi-site prospective evaluation of an AI-based digital assay for determining ER, PR, and HER2 status from H&E-stained breast cancer whole slide images

Salim Arslan, Panakeia Technologies, Cambridge, United Kingdom

P3-1-11

Whole-slide spatial mapping of tumor-infiltrating lymphocytes predicts recurrence-free survival in breast cancer

William C. Nenad, University of North Carolina, Chapel Hill, NC

P3-1-12

Prognostic performance of Stratipath Breast: a re-analysis with time to distant recurrence as endpoint

Stephanie Robertson, Karolinska Institutet and Stratipath AB, Solna, Sweden

P3-1-13

Continuous wearable monitoring identifies treatment-associated physiologic changes during breast cancer chemotherapy

Anish Kumar Simhal, Memorial Sloan Kettering Cancer Center, New York, NY

P3-1-14

Deep Learning of Multiparametric MRI Distinguishes Inflammatory from Non-Inflammatory Locally Advanced Breast Cancer Using Basic Clinical Criteria

Saleh Ramezani, University of Texas MD Anderson Cancer Center, Houston, TX

P3-1-15

Hiding in Plain Sight: Protein Network Topology Analysis Identifies Connectivity-Based Protein Drug Targets In Treatment Resistant Breast Cancer

Evan H Peikon, George Mason University, Manassas, VA

P3-1-16

Integrating MRI and AI-Derived Digital Pathology for Bimodal Prediction of Triple-Negative Breast Cancer Response to Neoadjuvant Therapy

Yutong Li, The University of Texas MD Anderson Cancer Center, Houston, TX

P3-1-17

Radiomic Texture Features Complement AI-CAD Scores for Malignancy Discrimination in BI-RADS 4 Breast Lesions

Carla R. Zeballos Torrez, University of Pennsylvania, Philadelphia, PA

P3-1-18

Automated Artificial Intelligence Solution Improves Accuracy and Reproducibility of HER2-ultralow Classification of Breast Cancer Samples

Manuela Vecsler, Ibex Medical Analytics, Tel Aviv, Israel

P3-1-19

Spatially resolved molecular heterogeneity in matched primary and metastatic breast cancer

Ryan S. Videgar-Laird, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-1-20

An ultrasonography and mammography-combined radiomics-deep learning model enhanced preoperative prediction of sentinel and non-sentinel lymph nodes metastases in breast cancers

XU XI-E, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China

P3-1-21

Emulating Randomized Controlled Trials With Hybrid Control Arms in Cancers Using Digital Twins

Hoa V Le, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-1-22

Long-term prognostic value of an MRI-derived recurrence tool in women with Hormone-receptor-positive, HER2-negative breast cancer: a retrospective, multi-center analysis

Matthew P Goetz, Mayo Clinic, Rochester, MN

P3-1-23

Real-world Multi-institutional Validation of a Multimodal Artificial Intelligence Model Predicting Early and Late Distant Metastasis Risk in Hormone Receptor-Positive, Node-Negative Breast Cancer

Shayna L. Showalter, University of Virginia, Charlottesville, VA

P3-1-24

Multimodal Foundation Models Unlock Transcriptomic Subtypes from Routine H&E Slides in TNBC

Loïc Le Bescond, AstraZeneca, Munich, Germany

P3-1-25

Single-cell-informed bulk RNA-seq resolves epithelial differentiation and stromal programs in breast cancer

Brian D Lehmann, Vanderbilt Health, Nashville, TN

P3-1-27

Relational modeling of continuous invasive lobular carcinoma biology reveals clinically relevant disease states

Rena Elkin, Memorial Sloan Kettering Cancer Center, New York, NY

P3-1-28

The Economic Impact of AI Triaging to Enable Same-day Diagnostic Work-up in Breast Cancer Screening Practice

Yannan Lin, UCLA, Los Angeles, CA

P3-1-29

Large Language Model-Driven Reconstruction and Optimization of an Open-Source Mammography AI System with Transcontinental Validation

Tianshen Hu, UT Southwestern Medical Center, Dallas, TX

P3-1-30

Diverging trajectories of baseline risk and radiotherapy benefit over 30 years after breast-conserving surgery

Carolina Fernandes Silva, Lisbon School of Medicine, Lisbon, Portugal

P3-2-01

Foundational Facial Emotion Recognition in Frontier AI Models: Implications for Automated Assistants in Post-Operative Breast Oncology

Claire Dvorak, Orlando Health, Orlando, FL

P3-2-02

Dynamic Explainable Artificial Intelligence Identifies Critical Recurrence Windows in Hormone Receptor-Negative Breast Cancer: A 14-Year Cohort of 960 Patients

Perya Abbasoglu, Istanbul Medipol University, Istanbul, Turkey

P3-2-03

Algorithm ranking is unstable: single-split selection of machine-learning models for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer

Dmytro Avierin, City Clinical Hospital #4, Dnipro, Ukraine

P3-2-04

Evaluation and failure analysis of a foundation model for automated breast tumor segmentation on post-contrast breast MRI

Leyla Ebrahimpour, Memorial Sloan Kettering Cancer Center, New York, NY

P3-2-05

Extracellular vesicle infrared fingerprints outperform whole plasma for stratifying metastatic from non metastatic breast cancer

Yara Cristina de Paiva Maia, Federal University of Uberlandia, Uberlândia, Brazil

P3-2-06

Three multimodal language models fail clinically actionable breast pathology in three different directions

Young-Joon Kang, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea, Republic of

P3-2-07

Ai-based prediction of genomic alterations, therapeutically relevant biomarkers, and clinical outcomes from breast cancer whole-slide images

Brian Laffin, Imagene AI, Miami, FL

P3-2-08

Impact of facial emotion recognition on AI large language model clinical behavior in a simulated surgical oncology post-operative visit

Claire Dvorak, Orlando Health, Orlando, FL

P3-2-09

Pangram50: a non-canonical, 50-gene, modular classifier that de-convolutes breast cancer into seven intrinsic subtypes and provides independently validated prognosis in triple-negative disease.

Jules Cohen, Stony Brook Cancer Center, Stony Brook, NY

P3-2-10

Can autonomous AI agents faithfully reproduce oncology data analyses? Evidence from breast cancer studies

Eunjung Yang, Yonsei University College of Medicine, Seoul, Korea, Republic of

P3-2-12

External Validation of TRINITY AI, a Multimodal H&E Based Deep Learning Model, for Breast Cancer Recurrence Risk Stratification: Concordance With Genomic Assays in 1001 Patients Across Multiple Institutions

Shivamurthy P M, 1Cell.Ai, Mumbai, India

P3-2-13

Machine Learning Identifies Patients at High Risk of Hospital Complications in Breast Cancer: A Nationwide database

Yanara A Bernal, Pontificia Universidad Católica de Chile, Santiago, Chile

P3-2-15

A Large Language Model-Derived Laboratory Frailty Assessment Captures a Distinct Dimension of Frailty in Older Patients With Breast Cancer: A Proof-of-Concept Study

Wesley Antônio Lopes de Lima, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil

P3-2-16

Can Attention-Based Deep Learning Improve Risk Stratification of Oncotype DX Recurrence Score from Breast DCE-MRI Radiomics?

Filiz Celebi, Istanbul Health and Technology University, Istanbul, Turkey

P3-2-17

Systematic multiomic ablation identifies copy-number alteration as the dominant portable and response associated biomarker of triple-negative breast cancer biology

Humaid Al Shamsi, Burjeel Cancer Institute, Abu Dhabi, United Arab Emirates

P3-2-18

Artificial Intelligence Reveals Prognostic Circulating Tumor-Immune Ecosystem Signatures in Prediction of Breast Cancer Outcomes

Huiping Liu, Northwestern University, Chicago, IL

P3-2-19

Self Organizing Map of Metabric Dataset recovers multiple known breast cancer categorizations

Alexander Ellis, Rice University, Houston, TX

P3-2-20

A minimal machine learning model for predicting biochemical treatment response in metastatic breast cancer

Charles Davis Kocher, Memorial Sloan Kettering Cancer Center, New York, NY

P3-2-21

A Virtual-Immunostain Risk Score Read from H&E Stratifies Outcome in Triple-Negative Breast Cancer

Megan Rothney, Pictor Labs, Inc., Los Angeles, CA

P3-2-22

A pan-cancer multiomic foundation model identifies copy-number instability as the dominant tissue-transferable biomarker linking triple-negative breast cancer to ovarian cancer and uterine carcinosarcoma

Humaid Alshamsi, Burjeel Cancer Institute, Abu Dhabi, United Arab Emirates

P3-2-23

Multiscale Anisotropy of Active Dense Tissue Relative to the Nipple: A Novel Architectural Signature of Malignancy

Andre Khalil, University of Maine, Orono, ME

P3-2-24

Guideline Concordance and Clinical Nuance: Comparing AI Tools With Practicing Oncologists in Metastatic Breast Cancer

Jasmin Hundal, Emory Univeristy, Atlanta, GA

P3-2-25

Predicting neoadjuvant therapy response from breast cancer core biopsies using multi-modal AI

Frederick M. Howard, UChicago, Chicago, IL

P3-2-27

Extracellular Vesicles-associated Regulatory Networks Provide Insights into Molecular Drivers of Breast Cancer Progression

Pedro Soares De Lima, Universidade de Sao Paulo, Sao Paulo, Brazil

P3-2-28

Disrupting Tumor Blood Supply: Computational Designing of Ankyrin Repeat Proteins (DARPins) and Antibodies Targeting Endosialin for CAR-T Therapy

Gaurav Sharma, Eigen Sciences, Apex, NC

P3-2-29

Development and Multi-Cohort Validation of a 179-Gene NGS-Based Multigene Assay for Predicting IHC Molecular Subtype in Breast Cancer

Hyemi Choi, DCGen, Co., Ltd., Seoul, Korea, Republic of

P3-2-30

Artificial Intelligence Based Prognostication Using Digital Pathology in Metastatic Hormone Receptor Positive and HER2 Negative Breast Cancer

Arya Mariam Roy, The Ohio State University, Columbus, OH

P3-3-01

A Multi-Agent Clinical Decision Support System for Personalized Breast Cancer Treatment Planning

Marina Campione, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy

P3-3-02

Toward Synthetic Patients in Breast Cancer: MRI- and Mechanism-Based Mathematical Modeling for Clinical Trial Design

Elisa Serafini, The University of Texas at Austin, Austin, TX

P3-3-03

Can AI Accurately Guide Axillary Surgery De-escalation? Testing Large Language Models Against NCCN, ASCO, and St. Gallen Criteria for Sentinel Lymph Node Biopsy Omission

Tiffany Calero, Los Robles Regional Medical Center, Thousand Oaks, CA

P3-3-04

A Continuous Progression Assessment Model for Breast Disease Based on Nipple Discharge Surface-Enhanced Raman Spectroscopy and Explainable Artificial Intelligence

Haoran Zhang, The Second Qilu Hospital of Shandong University, Jinan, China

P3-3-07

Evaluation of the effectiveness of postoperative follow-up of breast cancer diagnostic marker developed using artificial intelligence techniques

Yumi Kim, CHA Gangnam Medical Center, Seoul, Korea, Republic of

P3-3-08

Diagnostic Performance of Artificial Intelligence in Screening Mammography Across Breast Density Categories: A Systematic Review and Meta-analysis

Saad Abdul Kareem, University Of Maryland Capital Region Health, Largo, MD

P3-3-09

Layer-specific transfer learning improves multi-omics survival prediction in younger breast cancer patients

Wanru Guo, University of Maryland, Baltimore/ UM Greenebaum Comprehensive Cancer Center, Baltimore, MD

P3-3-10

Regulatory Manifold Dynamics identifies neoadjuvant chemotherapy non-response in HER2-negative breast cancer using an AI-learned multi-omics regulatory graph

Kristin Gleitsman, Eigen Bio, New York, CA

P3-3-11

Artificial Intelligence-Guided Biological Knowledge Integration Identifies FOXM1 and E2F1 as Master Regulators for mTOR Signaling

Cynthia Lee, Sapu Bioscience, LLC, San Diego, CA

P3-3-12

Improving the Calibration of PREDICT v3 for Early Stage Postmenopausal Hormone Receptor Positive Breast Cancer: A Transfer Learning and Ensemble Modeling Study

Hao Wang, The Ottawa Hospital, Ottawa, ON, Canada

P3-4-01

Breast MRI radiomics modeling for improved 5-year breast cancer risk assessment in elevated risk women

Anum Kazerouni, University of Washington, Seattle, WA

P3-4-02

Impact of a Polygenic Risk Score (PRS) for All Ancestries and the IBIS/Tyrer-Cuzick (TC) Model on WISDOM Trial Breast Cancer (BC) Screening Categorization in a Hereditary Cancer Testing Cohort

Elisha Hughes, Myriad Genetics, Inc., Salt Lake City, UT

P3-4-04

The WISDOM 2.0 Study: Initial Trends in Pathogenic Variants Among Women 30-39 in a Nationwide Risk-Based Breast Cancer Screening Trial

Hillary A Hsu, Duke University, Durham, NC

P3-4-05

Longitudinal blood-based biomarker trajectories improve breast cancer risk assessment in the prospective MD Anderson MERIT screening cohort

Ehsan Irajizad, The University of Texas M. D. Anderson Cancer Center, Houston, TX

P3-4-06

The glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide reduces obesity-associated breast cancer risk through circulating miRNA modulation and tumor subtype-specific gene expression changes.

Erin D Giles, University of Michigan, Ann Arbor, MI

P3-4-07

Breast cancer risk assessment and risk reclassification rates in an urban and majority Hispanic clinical population

Joseph De Nagy, Adventist Health / Loma Linda University, Los Angeles, CA

P3-4-08

Durability of Mammographic Breast Density Reduction Following 6 Months of Low-Dose Oral (Z)-Endoxifen in Premenopausal Women: 24-Month Follow-Up from the Randomized Phase 2 ATOS-016R Study

Hayley Erickson, Atossa Therapeutics Inc., Seattle, WA

P3-4-09

Timing of breast cancer surveillance: is the “10-years earlier” rule appropriate?

Edward Clifford, Baylor Scott and White Health, Grapevine, TX

P3-4-10

Mini-breast organoids from brca1/2 mutation carriers as a novel platform for progesterone-targeted breast cancer prevention

Twana Alkasalias, Karolinska Institutet, Stockholm, Sweden

P3-4-11

A Breast Cancer Risk Model Incorporating a Polygenic Score for All Ancestries: Clinical Validation in the Prospective All of Us Cohort

Timothy Simmons, Myriad Genetics, Inc., Salt Lake City, UT

P3-4-12

Age-dependent association between obesity and subsequent breast cancer risk following atypical hyperplasia

Greta Hiehle, Thomas Jefferson University, Philadelphia, PA

P3-4-13

Food processing and food contact material contaminants, their mixtures, and breast cancer risk in a large prospective cohort: the NutriNet-Santé study

Laurent Zelek, Université Sorbonne Paris Nord, Université Paris Cité, INSERM, INRAE, CNAM, CRESS, Bobigny, France

P3-4-14

Association of Background Parenchymal Enhancement and Breast Cancer Risk in Women with Dense Breasts undergoing Supplemental Screening

Anne Marie McCarthy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

P3-4-15

Identifying Women at High Risk for Triple Negative Breast Cancer Using Polygenic Risk Scores in a Screening Cohort: The WISDOM 2.0 Experience

Daisy Montoya, University of California, San Francisco, San Francisco, CA

P3-4-16

Improving Breast Cancer Screening Rates in Low Socioeconomic Zip Codes through Community Health Worker Outreach

Marshall Rosenberg, Lankenau Medical Center, Wynnewood, PA

P3-4-18

Molecular subtyping, pathologic complete response, and immune profiling of germline BRCA1/2-mutated HR+/HER2− breast cancer in the FLEX study

Amir Sonnenblick, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P3-4-19

Glucagon-like peptide 1 receptor agonists reduce obesity-mediated breast cancer risk and progression

Katherine Loree Cook, Wake Forest University School of Medicine, Winston Salem, NC

P3-4-20

10 years in the making: an update on genetic testing insights in a large diverse male breast cancer cohort

Mary Pritzlaff, Ambry Genetics, Aliso Viejo, CA

P3-4-21

Beneficial Omega-3 Supplementation for Oncological Mitigation (BOSOM) Trial: Role of Omega-3 Fatty Acids During Abrupt Involution on Breast Cancer Risk

Kate Ormiston, Ohio State University Medical Center, Columbus, OH

P3-4-22

L024: Reprogramming metabolism for hormone-agnostic breast cancer prevention and interception

Atieh Hajirahimkhan, Northwestern University, Chicago, IL

P3-4-24

Impact of glucagon-like peptide-1 (GLP-1) receptor agonists on breast density

Anne Marie Mccarthy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

P3-4-25

Third-generation sequencing uncovers novel germline structural variants associated with familial breast cancer susceptibility and therapeutic response

Xiaoying Qiao, PKUPH, Beijing Key Laboratory of AI-Enabled Data Governance and Precision Medicine for Breast Cancer, Beijing, China

P3-4-26

Identification of breast cancer-associated gene signatures predictive of pathological complete response

R.Keith Reeves, Duke University, Durham, NC

P3-4-27

Clinicopathologic predictors of low-risk Oncotype DX recurrence scores

Kellie Hon, Henry Ford Wyandotte Hospital, Wyandotte, MI

P3-4-28

Leveraging Epigenetic Loss of Imprinting as a Precision Model and Biomarker for Breast Cancer and Precancer Diagnosis and Risk Stratification

Miglena K. Komforti, Mayo Clinic Florida, Jacksonville, FL

P3-4-29

Impact of ambient air pollution on mammographic breast density and effect modification by smoking status in postmenopausal women, a study in Flandres, Belgium

Magda Johanna Vandeloo, University of Leuven, Leuven, Belgium

P3-5-01

Comparison of Invasive Breast Cancer Risk Models in the Kaiser Permanente Northern California Population Screening Cohort of 666,973 Women

Tejomay Gadgil, Kaiser Permanente Northern California, Pleasanton, CA

P3-5-02

Uptake of endocrine prevention in women with germline pathogenic variants in moderate and high penetrance breast cancer susceptibility genes

Natasha Stonebanks Cuillerier, McGill University, Montreal, QC, Canada

P3-5-03

Spectrum and population burden of germline pathogenic variants beyond BRCA1 and BRCA2:genotype-phenotype correlations in Mexican women with breast cancer, and population-based frequencies of recurrent variants in a large Mexican cohort

Yanin Chavarri-Guerra, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

P3-5-04

Closing the BRCA identification gap: an Italian modeling study of cascade genetic testing for hereditary breast and ovarian cancer

Alberto Zambelli, ASST Papa Giovanni XXIII, Bergamo, Italy

P3-5-05

Germline Mutation Landscape of ER-Low Breast Cancer: Closer to Hormone Receptor-Positive Than Triple-Negative Disease

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P3-5-06

Association between glucagon-like peptide-1 receptor agonist treatment and changes in mammographic density

J Alex B Gibbons, Columbia University, New York, NY

P3-5-07

Prospective Identification of Breast Cancer Genetics Evaluation Gaps in the MERIT Mammography Cohort

Banu Arun, MD Anderson Cancer Center, Houston, TX

P3-5-08

Germline pathogenic variant yield across HER2-low subgroups in HR-positive/HER2-negative breast cancer: a study of 1,054 patients

Ioannis Natsiopoulos, Medical Center, Thessaloniki, Greece

P3-5-09

Gene-specific tumor phenotypes among patients with germline BRCA1, BRCA2, PALB2, and CHEK2 mutations: A comparative analysis from a large Middle Eastern breast cancer cohort

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P3-5-10

Digital point-of-care education to support BRCA testing discussions

Susan Joy Friedman, Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL

P3-5-11

Medical management of patients with HER2-negative early breast cancer and germline pathogenic variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2

Vishnu Prasath, The Ohio State University College of Medicine, Columbus, OH

P3-5-12

Feasibility of microbiome profiling in archival breast tissue: Assessment of DNA yield and quality

Sarah Nyante, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-5-13

Real-world patterns of adjuvant treatment in patients with early breast cancer (eBC) carrying germline pathogenic variants (PV) in BRCA1, BRCA2 and selected homologous recombination repair genes: final results from the ROAD study

Pablo Tolosa Ortega, 12 de Octubre University Hospital, Madrid, Spain

P3-5-14

Text message-based tyrer-cuzick risk assessment prior to mammography and identification of germline genetic variants: real-world experience from a community health system

Suma Sri Chennapragada, Mercy Hospital Fort Smith, Fort Smith, AR

P3-5-15

Missed Opportunities in High Risk Breast Cancer Screening – Real World Implementation of Tyrer Cuzick Risk Assessment in a Large Health System

Marion White, Allegheny Health Network, Pittsburgh, PA

P3-5-16

Reproductive Care as a Gateway to Precision Breast Cancer Risk Assessment: Initial Findings from the FOCUS Study

Melissa K Frey, Weill Cornell Medicine, New York, NY

P3-5-17

Medium‑Chain fatty acid-induced metabolic rewiring drives hallmarks of mesenchymal triple‑negative breast cancer

Mariana Bustamante Eduardo, Northwestern University Feinberg School of Medicine, Chicago, IL

P3-5-18

Prevention Uptake with Risk-Reducing Medication within the WISDOM (Women Informed to Screen Depending on Measures of risk) 1.0 Study Cohort

Jackelyn J Moya, UCSF, San Francisco, CA

P3-5-19

Evaluating Lifetime Breast Cancer Risk in Unaffected Menopausal-age Women to Potentially Inform Hormone Therapy Initiation

Edith Smith, Myriad Genetics, Inc., Salt Lake City, UT

P3-5-20

Exploring Risk Perceptions and Needs in Patients with Elevated Tyrer Cuzick Risk Scores to Inform Digital Health Tool Adaptation

Emma Sears, University of Utah, Salt Lake City, UT

P3-5-21

Evaluating the outcomes of mainstream genetic testing for individuals with breast cancer

Cassandra Marie Baldry, McGill University, Montreal, QC, Canada

P3-5-22

Breast Cancer Risk Among Healthcare Professionals with Occupational Radiation Exposure: A Systematic Review and Meta-analysis

Alan G S F Pinho, Federal University of Bahia, Salvador, Brazil

P3-5-24

Differential associations of body mass index with circulating estrogens among US pre- and postmenopausal women

Lin Yang, Cancer Care Alberta, CALGARY, AB, Canada

P3-5-25

Background parenchymal enhancement reflects distinct endocrine-responsive and immune-modulatory epithelial states in the normal breast

Jennifer M Rosenbluth, University of California, San Francisco, San Francisco, CA

P3-5-26

Unfavorable metabolic phenotype in breast cancer women: a case-control study

Isabelle R. Novelli, University of São Paulo, São Paulo, Brazil

P3-5-27

Evaluating NMD as a Mechanistic Basis for the BRCA2 Exon 11 Genotype-Phenotype Correlation in Cancer Risk and Treatment Response

Fabio Giuntini, University of Pennsylvania, PHILADELPHIA, PA

P3-5-28

Clinical Profile and Outcomes of Risk-Reducing Nipple-Sparing Mastectomy with Implant-Based Reconstruction Stratified by Cancer Predisposition Gene Pathogenic Variants: A Multicenter Cohort Study.

Francisco Pimentel Cavalcante, Hospital Geral de Fortaleza, Fortaleza, Brazil

P3-5-29

Anogenital distance as a clinical marker of prenatal hormonal programming: implications for breast cancers

Domingo Sánchez, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

P3-5-30

Genetic Testing Uptake and Outcomes After Telephone Outreach Among Previously Untested Breast Cancer Survivors in the Bronx

Kassandra Lanza, Albert Einstein College of Medicine, Bronx, NY

P3-6-01

Her2-driven breast cancer phenotype in Li-Fraumeni syndrome: Insights from a peruvian national cohort

Pamela Mora, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

P3-6-02

Clinicopathologic and Genomic Correlates of TRPS1 Amplification in Breast Cancer

Ahmed Hesham Al Sharie, Southeast Health, Dothan, AL

P3-6-03

From Germline Testing to Precision Prevention: A Statewide Cascade Screening Program Enables Early Cancer Detection in High-Risk Families

Elisangela de Paula Silveira-Lacerda, Universidade Federal de Goiás, Goiânia, Brazil

P3-6-04

Long-term clinical outcomes following germline genetic testing in hereditary breast cancer predisposition carriers: a real-world cohort study

Isalia Miguel, IPO Lisboa, Lisbon, Portugal

P3-6-05

Germline mirSNPs Identify Women at Increased Risk of Menopausal Hormonal Therapy-Associated Breast Cancer

Joanne B Weidhaas, UCLA, Los Angeles, CA

P3-6-06

Higher Adherence to HEDIS Breast Cancer Screening Among Women Receiving Care Through a Specialized Telehealth Midlife Women's Health Clinic: A Retrospective Cohort Study

Cynthia Castro Sweet, Midi Health, Inc., Palo Alto, CA

P3-6-07

Initial and Repeat Oncotype DX Breast Recurrence Scores in Patients with Breast Cancer Locoregional Recurrence

Lauren M Granat, Cleveland Clinic, Cleveland, OH

P3-6-08

Uptake of guideline-concordant breast MRI screening and risk-reducing surgeries among women with pathogenic variants in high- and moderate-penetrance breast cancer predisposition genes

Alex Jiang, NYP-Columbia, New York, NY

P3-6-09

Developing a Nurse-led model of care for individuals with breast, ovarian and pancreatic cancer to access treatment focused genetic testing

Jasmina Bojadzieva, Austin Health, Melbourne, Australia

P3-6-10

Predictors of confirmatory germline genetic testing after identification of BRCA1, BRCA2, or PALB2 pathogenic variants on somatic tumor testing among patients with cancer

Vicky Ro, NYP-Columbia, New York, NY

P3-6-11

Prospective Study of Quantitative Broadband Diffuse Optical Spectroscopy for Differential Diagnosis of Suspicious Breast Lesions

Alice M. Police, Northwell Health, Sleepy Hollow, NY

P3-6-12

Development and Validation of a Large Language Model-Based Pipeline to Evaluate the Quality of Social Media Videos on Hereditary Breast Cancer

Victoria Hayman, McGill University, Montréal, QC, Canada

P3-6-12

Germline Mutations in Young Breast Cancer: a 10-Year Single-Center Cohort from Spain

JUNCAL CLAROS, HOSPITAL UNIVERSITARIO SEVERO OCHOA, MADRID, Spain

P3-6-14

Differential symptom burden in affected versus unaffected women at a certified hereditary breast and ovarian cancer center: associations with complementary medicine use and support preferences

Annika Hielbig, University Hospital Schleswig-Holstein Campus Luebeck; University of Luebeck, Luebeck, Germany

P3-6-15

Variants of Uncertain Significance in High-Risk Breast Cancer Patients from Bolivia: Real-World Experience from the First National Cancer Genetics Program

Diego Montenegro, Intituto Oncologico del Oriente Boliviano, Santa cruz de la sierra, Bolivia, Plurinational State of

P3-6-16

Concurrent Acute Venous Thromboembolism and Thrombocytopenia in Adults Hospitalized With Breast Cancer: In-Hospital Outcomes and Resource Use (2016-2020)

Milan Regmi, Southeast Health Medical Center, Dothan, AL

P3-6-17

Functionalhomologous recombination deficiency and environmental exposure in early-onset breast cancer

Matilde Corianò, University of Parma, Parma, Italy

P3-6-18

Closing the Distance: Breast Cancer Screening Among Women Veterans in a National High-Risk Tele-Oncology Clinic

Michela Fabricius, Duke University, Durham, NC

P3-6-19

Structure-aware isoform fine-mapping with expanded long-read breast transcriptome assemblies refines causal isoform discovery for breast cancer risk and mammographic density

Taylor Head, The University of Texas MD Anderson Cancer Center, Houston, TX

P3-6-20

A Review of Patients with A Breast Cancer Gene Variant Undergoing Risk Reduction Mastectomies-A South West Wales, UK Experience

Saira Khawaja, Prince Philip Hospital, Llanelli, United Kingdom

P3-6-21

Prevalence, spectrum of germline variants, and cascade testing performance in a hereditary breast cancer program in chile

Militza Petric, Clinica Universidad de los Andes, Santiago, Chile

P3-6-22

Early Biological Alterations in a Heterozygous BRCA1 Germline Mutation Model Inform Breast Cancer Risk Assessment

Jingjing Chen, The University of Kansas Medical Center, Kansas City, KS

P3-6-23

Lead time trajectory of blood-based protein biomarkers for improved breast cancer risk assessment based on repeat testing

Johannes Fahrmann, The University of Texas M. D. Anderson Cancer Center, Houston, TX

P3-6-24

Determinants of Cascade Genetic Testing Uptake and identifying Opportunities to Reduce Disparities in Hereditary Cancer Care

Catherine A Murphy, Odette Cancer Centre, Toronto, ON, Canada

P3-6-25

Concordance between a digital family history tool and genetic counselor-elicited pedigrees for hereditary cancer risk assessment in a diverse population

Marlee Pincus, Columbia University Irving Medical Center, New York, NY

P3-6-26

Outcomes of Younger Breast Cancer Patients: A Regional Cancer Centre Experience

Melissa Hacio, Thunder Bay Regional Health Research Institute, Thunder Bay, ON, Canada

P3-6-27

Per- and polyfluoroalkyl substances accumulation in normal and cancerous breast tissues and plasma-tissue partitioning

Michele L Cote, Indiana University, Indianapolis, Indianapolis, IN

P3-6-28

Clinicopathologic Characteristics, Treatment Patterns, and Eligibility for Adjuvant Treatment Escalation in Patients Undergoing Rapid Genetic Testing for Early Breast Cancer

Catherine A Murphy, Odette Cancer Centre, Toronto, ON, Canada

P3-6-29

Breast Density Change and Breast Cancer Incidence Among Real-World Users of Conjugated Estrogens/Bazedoxifene

Melissa Tempest, Yale University, New Haven, CT

P3-6-30

Implementation of an Electronic Medical Record Clinical Decision Support Facilitated Mainstream Genetic Testing Workflow in the Breast Surgery Clinic

Allison DePersia, Endeavor Health, Evanston, IL

P3-3-30

Genetic counseling in young patients with breast cancer: from indication to result, gaps in genetic testing

Valentina Salvador, Clinica Davila, Santiago, Chile

P3-3-29

Accuracy of the tyrer-cuzick model (ibis) in detection of pathogenic or likely pathogenic germline variants in genes associated with hereditary breast cancer in brazilian high-risk population.

Cesar Cabello, State University of campinas – UNICAMP, campinas, Brazil

P3-7-01

Breast Cancer Biomarker Testing Capacity in Resource-Limited Settings: Evidence from Site Assessments and the Case for STRAT4 Implementation

Mei Ching Ong, The Max Foundation, Seattle, WA

P3-7-02

Realistic Simulation as a Training Strategy for Primary Health Care in Breast Cancer: The Experience of the Goiás Todo Rosa Program

Rosemar Macedo Sousa Rahal, Federal University of Goiás, Goiania, Brazil

P3-7-03

Survivorship Care Plan Receipt and Overall Survival in Early-Stage Breast Cancer

Anne H Blaes, University of Minnesota, Minneapolis, MN

P3-7-04

21-gene recurrence score test for chemotherapy decision-making in early breast cancer: a swiss cost effectiveness analysis

Elena Diana Chiru, Cantonal Hospital Basel-Landschaft, Liestal, Switzerland

P3-7-05

Multidisciplinary Team Engagement Across Early-Stage and Metastatic Breast Cancer: A Pilot Multi-Center Assessment in US Centers of Excellence

Manali Bhave, Emory University, Atlanta, GA

P3-7-06

Individual and system-level drivers of decreased outcomes among rural breast cancer survivors

Michael T Halpern, Kate Marmion School of Public Health, University of Texas San Antonio, San Antonio, TX

P3-7-07

Fertility preservation and chemotherapy timeliness among patients diagnosed with breast cancer at age 40 or younger in a multi-site breast cancer program with an integrated fertility center

Shivali Devjani, NYU Langone Health / Grossman School of Medicine, New York, NY

P3-7-09

The State of Breast Cancer Clinical Trials 2026

Megan Majocha, Susan G. Komen, Dallas, TX

P3-7-10

Impact of a Patient Navigation Program on Insurance-Based Disparities in Breast Cancer Screening and Diagnostic Completion: A 10-Year Institutional Analysis of the Penn Medicine Breast Health Initiative

Cailin O'Connell, University of Pennsylvania, Philadelphia, PA

P3-7-12

Cost-effectiveness analysis of ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus endocrine therapy (ET) alone in high-risk stage II and III HR+/HER2− early breast cancer (EBC): A Hong Kong public healthcare perspective

Winnie Yeo, Chinese University of Hong Kong, Hong Kong, Hong Kong

P3-7-13

Identifying Gaps in Antibody-Drug Conjugate Toxicity Monitoring and Care Coordination: Baseline Findings from a Multidisciplinary Quality Improvement Initiative

Namita Ruhela, Baptist Health Herbert Wertheim Cancer Institute, Miami, FL

P3-7-14

Embedding a multilevel implementation toolkit in OPTIMA-Young to enhance inclusive recruitment, shared decision-making, and patient experience

Maria Alice Franzoi, Gustave Roussy, Villejuif Cedex, France

P3-7-15

A Regional Academic Platform to Advance Contextualized Precision Oncology in Latin America: The LABCA Molecular Tumor Board

Denis Ulises Landaverde, Mexico Hospital, San Jose, Costa Rica

P3-7-16

Inflammatory Breast Cancer Recognition Among Rural Primary Care Providers: Confidence, Resource Gaps, and Comparisons to Urban Practices

Alexandra Bennion, Medical University of South Carolina, Charleston, SC

P3-7-17

Associations of Individual Comorbidities and Comorbidity Burden with Premature Chemotherapy Cessation among Women with Stage 1-3 Breast Cancer

Joel A. Begay, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-7-18

Breast cancer-specific and competing mortality in adults aged ≥70 years treated with first-line CDK4/6 inhibitors plus endocrine therapy for HR+/HER2- metastatic breast cancer: Results from Alliance A171601

Minji Lee, Mayo Clinic, Rochester, MN

P3-7-19

Beyond Technology: Communication, Trust, and Digital Anxiety Shape Teleoncology Acceptance in Breast Cancer Care

Renata Kelemenic-Drazin, General Hospital Varazdin, Varazdin, Croatia

P3-7-20

Perceptions and Experiences of Transgender and Gender-Diverse Individuals on Breast Cancer Screening

Chandler S Cortina, Medical College of Wisconsin, Milwaukee, WI

P3-7-21

Prevalence of oncology treatment non-adherence and psychosocial distress in breast cancer patients enrolled in a collaborative care program

Alanna Robinson, Cerula Care, Hardford, CT

P3-7-22

Financial Toxicity and Quality of Life in Patients with Breast Cancer: Preliminary Results from the OncoValue</b>

Julio Araujo, OncoCenter, São Paulo, Brazil

P3-7-23

Breast cancer and COVID-19 in Morocco: Evidence of delayed diagnosis and aggressive post-pandemic presentation

Radia El gui, Faculty of science, Ibn Tofail university, Kenitra, Morocco

P3-7-24

Factors associated with patient portal access and use among Chinese American and Non-Hispanic White breast cancer survivors

Maryann Kwa, NYU Perlmutter Cancer Center, NYU Langone Health, New York, NY

P3-7-25

Evaluation of a digital patient-monitoring tool in breast oncology

Brigitte Poirier, CHU de Quebec – Universite Laval, Quebec City, QC, Canada

P3-7-26

Breast Cancer Brain Metastases in Rural America: Comparable Outcomes Driven by Systemic Therapy, Not Rurality

Charishma Potla, West Virginia University, Morgantown, WV

P3-7-27

Communication Challenges and Care Complexity in Invasive Lobular Carcinoma: Results from an International Patient Survey

Claire Fanning, University of Michigan Medical School, Ann Arbor, MI

P3-7-28

Patient Voices beyond borders

Karadawi Eltag Nabeeha, Hamad corporation, Doha, Qatar

P3-7-29

Screening mammography as an opportunity to identify cardiovascular risk factor burden: a national analysis of 104,361 U.S. women

Gabriela Perez Alvarez, Florida International University, Miami, FL

P3-7-30

A computational framework to prioritize systemic therapy implementation for global breast cancer outcome equity in resource-constrained settings

Federica Miglietta, University of Padova, Padova, Italy

P3-8-01

Development of an educational technology on high-risk breast cancer screening for women in a country with low health literacy

Amanda Araújo Dias, Hospital Nove de Julho, São Paulo, Brazil

P3-8-02

Nationwide Implementation of Precision Oncology Biomarkers and Systemic Treatment in Breast Cancer: Results from the Medi-LINE 2025 Study

Bela Mrinakova, Faculty of Medicine, Comenius University and St. Elisabeth Cancer Institute, Bratislava, Slovakia

P3-8-03

Access to perioperative pembrolizumab for high-risk early-stage triple-negative breast cancer in Brazil's Unified Public Health System

Angela Theresa Zuffo Yabrude, Universidade Regional de Blumenau, Blumenau, Brazil

P3-8-04

Rapid Access Genetic Testing Outcomes for Breast Cancer Diagnosed ≤ 65 Years Old

Jessica Ebrahimzadeh, Penn Medicine, Philadelphia, PA

P3-8-05

Patient-informed exercise program design during neoadjuvant chemo-immunotherapy for triple-negative breast cancer: a qualitative focus group study to inform pilot trial design

Yolcar Chamorro, Baptist Health Herbert Wertheim Cancer Institute, Miami, FL

P3-8-06

Real-world access barriers, treatment interruption, and discontinuation of conjugated estrogens/bazedoxifene

Melissa Tempest, Yale University, New Haven, CT

P3-8-07

Identifying care-delivery gaps in cardiac monitoring in individuals treated with cardiotoxic cancer therapy

Andrew Bohannon, Skribe Medical, Mill Valley, CA

P3-8-08

Understanding Experiences related to Breast Imaging and Participation in Research: Surveys and Discussions with Alberta Women

Elise Fear, University of Calgary, Calgary, AB, Canada

P3-8-09

Upstream Barriers to Breast Reconstruction in Patients with Obesity: A Survey of Surgeon Referral Patterns

Luz E Mata-Iriarte, Rush Medical College, Chicago, IL

P3-8-10

Decision-making in a complex clinical context: endocrine therapy initiation and persistence in oncotype-tested breast cancer

Emily Gong, NYU, New York, NY

P3-8-11

Improving timely access to radiotherapy for breast cancer: reducing waiting times at a cancer center in Mexico, a SQUIRE 2.0-based quality improvement project.

Daniel Rivera-Sanchez, National Cancer Institute of Mexico, Tlalpan, Mexico

P3-8-12

From Advocacy to Public Policy – Civil Society Initiative Leading to the Incorporation of BRCA1/2 Genetic Testing into Brazil's Public Health System

Maira Caleffi, FEMAMA, Porto ALegre, Brazil

P3-8-13

Hospital Admissions and Socioeconomic Factors Predict Supportive Care Utilization in Metastatic Breast Cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

P3-8-15

Associations of mental health status with concurrent benzodiazepine and opioid use among older adults with breast cancer

Savannah R Gonzales, Dartmouth College, Hanover, NH

P3-8-16

Implementation of a Multidisciplinary Oncofertility Referral Pathway Improves Timely Fertility Preservation Without Delaying Cancer Treatment in Young Women With Breast Cancer

Hsiu-Hsuan Chan, Taichung Veterans General Hospital, Taichung, Taiwan

P3-8-17

Length and structural characteristics of informed consent documents in breast cancer clinical trials

Manuel Perez-Martin, Hospital Clínico San Carlos, Madrid, Spain

P3-8-18

A national analysis of energy cost savings and resource optimization in breast mammography

Katie E Lichter, Dartmouth Cancer Center, Lebanon, NH

P3-8-19

Guideline adherence gaps in neoadjuvant chemotherapy for locally advanced breast cancer in the Brazilian public health system

Renata Colombo Bonadio, Oncologia D´or, São Paulo, Brazil

P3-8-20

Treatment Patterns and Outcomes of Older Adults with Non-metastatic Breast Cancer: A Nationwide Population-based Study of 265,729 Patients in Brazil (GBECAM-2505)

MAX S. MANO, Grupo Brasileiro de Estudos em Cancer de Mama (GBECAM) and Einstein Hospital Israelita, Sao Paulo, Brazil

P3-8-21

A Novel Emergency Department Model for Expanding Access to Genetic Testing and Cancer Prevention Services

Cammeo Mauntel-Medici, University of Illinois at Chicago, Chicago, IL

P3-8-22

Quality and Readability of Online Materials Related to Radiation Therapy for Breast Cancer

Sarah Elisabeth Horn, Boston University Chobanian & Avedisian School of Medicine, Boston, MA

P3-8-23

Mastology: A National Assessment of Workforce Characteristics, Remuneration and Professional Satisfaction among breast surgeons in Brazil.

Jordana Faria Bessa, Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil

P3-8-24

Time to Treatment Initiation in Breast Cancer Before, During, and After the COVID-19 Pandemic

Joseph Zouein, Cooper University Health Care, Camden, NJ

P3-8-25

Dnr Status and End-of-Life Resource Utilization in Metastatic Breast Cancer : A National Study

Lydia Francis, UTHSCSA, San Antonio, TX

P3-8-26

Early outcomes and lessons learned from implementation of a treatment access program for advanced breast cancer in Nepal and Cambodia

Mei Ching Ong, The Max Foundation, Seattle, WA

P3-8-27

Narrowing Black-White Disparities and Reducing Late-Stage Breast Cancer Diagnosis Through Patient Navigation in Underserved Communities

Angelique Griffin, Gilead Sciences, Foster City, CA

P3-8-30

Knowledge, Attitudes, and Exercise Engagement Among Women Receiving Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer: A Qualitative Focus Group Study

Yolcar Chamorro, Baptist Health Herbert Wertheim Cancer Institute, Miami, FL

P3-9-01

Rethinking care fragmentation among patients with ER+/HER2− breast cancer

Danting Yang, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-9-02

Patient Navigation Improves Timely Treatment and Five-Year Survival Among Women with Breast Cancer in Brazil: A Prospective Cohort Study

SANDRA GIOIA, State Department of Health, Rio de Janeiro, Brazil

P3-9-03

From policy to access: tracking breast cancer screening coverage laws

Susan J Friedman, Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL

P3-9-04

Electronic health record (EHR) advisory for fertility preservation in patients with breast cancer: implementation and workflow outcomes

Amye J Tevaarwerk, Mayo Clinic, Rochester, MN

P3-9-05

Telephone Reminder to Improve Mammography Uptake Among Women Overdue for Screening in a Tertiary Referral Hospital in Northeastern Mexico. A Randomized Controlled Trial

Adela Gloryle Solis Lopez, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico

P3-9-06

Closing the Coverage Gap: A Decade of State Policy to Eliminate Cost Barriers to Breast Imaging

Rebecca Birch, Susan G. Komen, Dallas, TX

P3-9-07

Racial inequities in advanced-stage breast cancer among young women in Brazil, 2015-2024

Isabella Figueiredo, HCOR, Sao Paulo, Brazil

P3-9-08

Perspectives from oncologists on the value of treatments for advanced HR-positive, HER2-negative breast cancer

Haydee Cristina Verduzco-Aguirre, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico

P3-9-09

Hpv vaccination in women with breast cancer: low uptake in a brazilian population receiving private healthcare

Amanda Dias, Hospital Nove de Julho, São Paulo, Brazil

P3-9-10

Improving mammography yield in resource-limited settings through breast cancer risk stratification and symptom assessment

Alejandra Lazo, Aditum Consulting Group, Mexico City, Mexico

P3-9-11

Assessing Breast Cancer Risk in Young Women in an Under-Resourced Patient Population

Martha Welman, Neighborhood Health, Alexandria, VA

P3-9-12

Breast Cancer Lags Behind in Pretreatment DPYD Testing Before Fluoropyrimidine Chemotherapy: A National EHR Study

Michael D Dang, UT Southwestern Medical Center, Dallas, TX

P3-9-13

Health resource utilization after the incorporation of pembrolizumab for early triple negative breast cancer.

Federico Waisberg, Instituto Alexander Fleming, Buenos Aires, Argentina

P3-9-14

Cross-border breast cancer care in women from portuguese-speaking african countries treated at a european comprehensive cancer center

Amanda Hirschfeld, Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

P3-9-15

Global economic burden of premature breast cancer mortality across 185 countries by World Bank income groups

Natalia Libonati, Queen's University, Kingston, ON, Canada

P3-9-16

Breast Specialist Care and Shared Decision-Making Across the SDM Distribution in Metastatic Breast Cancer: A Multivariable Quantile Regression Analysis

Mya Roberson, University of North Carolina at Chapel Hill, Chapel Hill, NC

P3-9-17

Cardiotoxicity Disparities by Race, Ethnicity and Socioeconomic Status after Anthracycline or HER-2 Targeted Therapy: A Systematic Review

Sharanya Tripathi, Saint Vincent Hospital, Worcester, MA

P3-9-18

Return to screening: Adherence to biennial mammography guidelines among women screened on a mobile cancer screening van

Amy Leader, Thomas Jefferson University, Philadelphia, PA

P3-9-19

Positive Impacts of Integrating Community Health Workers in Mammography within an Urban Safety-Net Hospital

Jeanette Avila, Sinai Chicago, Chicago, IL

P3-9-20

A Comprehensive Online CME Curriculum Improves Clinical Understanding of Novel and Emerging Therapies in Breast Cancer Across the Multidisciplinary Care Team

Sarah Waterhouse, Medscape Global, London, United Kingdom

P3-9-21

Improving Data Systems for Clinical Impact Across the Pre-Diagnostic Journey: Lessons from a Multi-Site Breast Cancer Screening Implementation Pilot

Hilary Armstrong, Gilead Sciences, Foster City, CA

P3-13-18

Survival Outcomes in HER2+ De Novo Metastatic Breast Cancer Treated with Local Therapies: An NCDB Analysis

Nicole Casasanta, Yale Cancer Center, Yale School of Medicine, New Haven, CT

P3-13-20

A DESTINY-Breast09 analysis of HER2 status and baseline genomic alterations identified in circulating tumor (ct)DNA from patients with HER2+ metastatic breast cancer (mBC) treated with first line (1L) trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP)

Andreas Schneeweiss, University Hospital and German Cancer Research Center, Heidelberg, Germany

P3-13-21

Genomic landscape of HER2-positive (HER2+) metastatic breast cancer (MBC): Analyses from the AVIATOR trial (TBCRC045)

Elia Segui, Dana-Farber Cancer Institute, Boston, MA

P3-13-22

Antitumor activity of zongertinib plus zanidatamab in preclinical models of HER2-positive metastatic breast cancer (mBC): rationale for phase Ib clinical evaluation

Sima Khazaei, The University of Texas MD Anderson Cancer Center, Houston, TX

P3-13-23

Real-world outcomes of TTC after T-DXd in HER2+ metastatic breast cancer: data from the ESME French database

William Jacot, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France

P3-13-24

Survival differences between de novo and recurrent HER2-positive metastatic breast cancer: A systematic review and meta-analysis

Taiga Komatsu, Mount Sinai Morningside/West, New York, NY

P3-13-26

Pooled Efficacy and Safety of CDK4/6 Inhibition in Hormone Receptor-Positive/HER2-Positive Advanced Breast Cancer: A Systematic Review and Meta-analysis

Natália Cristina Cardoso Nunes, Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Rio de Janeiro, Brazil

P3-13-27

The TucErbiT Trial. Tucatinib/Eribulin/Trastuzumab for Metastatic HER2 Positive Metastatic Breast Cancer

henry G kaplan, Swedish Cancer Institute, Seattle, WA

P3-13-28

Her2+ cns surveillance: a study of the feasibility of randomising women and men with her2 positive metastatic breast cancer to central nervous system surveillance versus no surveillance

Talvinder Bhogal, Institute of Systems, Molecular and Integrative Biology, Liverpool, United Kingdom

P3-13-30

First-line (1L) pertuzumab-based treatment patterns and outcomes of HER2-positive (HER2+) metastatic breast cancer (BC) in France: the LongHER study

Thibault De la Motte Rouge, Centre Eugène Marquis, Rennes, France

P3-14-01

Tucatinib, Trastuzumab, Capecitabine and Stereotactic Radiosurgery in the Management of HER2 Positive Breast Cancer Brain Metastases: A Multi-Institutional Analysis

Levi Martinka, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

P3-14-02

Incidental Versus Symptomatic Detection of CNS Metastases in HER2-Positive Metastatic Breast Cancer

Emmanuelle Alaluf, Sheba Medical Center, Ramat Gan, Tel Hashomer, Israel

P3-14-03

Real-world effectiveness of trastuzumab deruxtecan in HER2-positive metastatic breast cancer (MBC): results from the multicenter observational ENHESUR cohort in Southern Spain

Ana Godoy-Ortiz, Hospital Universitario Virgen de la Victoria de Malaga, Málaga, Spain

P3-14-05

Esr1 Mutations in HER2-Positive Breast Cancer: A Clinicogenomic Analysis

Alfia Bilal, Memorial Sloan Kettering Cancer Center, New York, NY

P3-14-06

ESR1 Amplification: A Distinct Endocrine Resistance Pathway Enriched in Lobular Breast Cancer

Liu Liu, Brown University Health, Warren Alpert Medical School of Brown University, Providence, RI

P3-14-07

Patterns of relapse and outcomes of metastatic breast cancer patients exposed to T-DM1 in the early setting: insights from the real-world ESME database.

Meriam Dakir, Institut du Cancer de Montpellier, Montpellier, France

P3-14-08

Central nervous system outcomes with tucatinib-based regimens and trastuzumab deruxtecan in HER2-positive metastatic breast cancer: a systematic review and meta-analysis

Elias Tayar, HCA Healthcare Clear Lake, Webster, TX

P3-14-09

Abnormal Methionine Metabolism Suppresses B-Cell Immunity to Drive HER2-ADC Resistance in HR+/HER2+ Breast Cancer

Qun Lin, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou,China, China

P3-14-10

Attrition Doesn't Stop at First Line: Tracking Treatment Loss Across the Metastatic Journey in HER2-Positive Breast Cancer in a Real-World Cohort

Manuela Del Rio Navarrete da Fonseca, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil

P3-14-11

A Preclinical Study of a NIR-II Fluorescent Molecular Probe for Accurate Assessment of Sentinel Lymph Node Metastasis in HER2-Positive Breast Cancer

Hongyu Chen, xiamen university, xiamen, China

P3-14-12

Intracranial Efficacy of Antibody-Drug Conjugates in Breast Cancer Brain Metastases: A Systematic Review and Meta-Analysis

Zaheer Qureshi, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY

P3-14-13

Pik3ca mutational landscape and clinical implications in her2-positive advanced breast cancer: a multicenter real-world study

Ouchen Wang, The first affiliated hospital of Wenzhou Medical University, Zhejiang Province, China

P3-14-14

Real-world outcomes of metronomic vinorelbine across advanced breast cancer subtypes: a multi-center analysis focusing on anti-her2 maintenance therapy

Chinyao Lin, Taichung Tzu Chi Hospital, Taichung, Taiwan

P3-14-15

Multicentric Real-World Safety and Effectiveness Analysis of Trastuzumab Deruxtecan Therapy in Metastatic HER2-positive Breast Cancer Patients in Croatia

Marija Križić, University Hospital Centre Zagreb, Zagreb, Croatia

P3-14-17

Treatment discontinuation with trastuzumab deruxtecan in HER2-positive metastatic breast cancer: a systematic literature review

Alex Bates, Jazz Pharmaceuticals, London, United Kingdom

P3-14-18

Real-world (RW) treatment modification, discontinuation, and safety management of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive (HER2+) metastatic breast cancer (mBC) in the United States (US)

Maki Inoue-Choi, AstraZeneca, Gaithersburg, MD

P3-14-19

Efficacy and Safety of Dual versus Single-Agent anti-HER2 Blockade in Metastatic HER2-positive Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Enrique Alanya, Edgardo Rebagliati Martins Hospital, Lima, Peru

P3-14-20

Selection of First-Line and Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) in an Evolving Treatment Landscape: A Survey of General Medical Oncologists (GMOs)

Kevin H Pang, Research To Practice, Key Biscayne, FL

P3-14-21

Real-world outcomes among older adults receiving trastuzumab deruxtecan for breast cancer: a propensity-matched trinetx analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P3-14-22

Comparative Real-World Safety of Abemaciclib, Palbociclib, and Ribociclib in Endocrine-Treated ER+/HER2− Breast Cancer

Amrit Sandhu, Drexel University College of Medicine, Philadelphia, PA

P3-14-23

Prognostic comparison of deep partial response versus complete response and non-deep partial response with trastuzumab deruxtecan in HER2-positive metastatic breast cancer

Yuka Niwa, Aichi Cancer Center, Nagoya, Japan

P3-14-24

A DESTINY-Breast09 analysis of outcomes by baseline burden of disease in patients with HER2+ metastatic breast cancer (mBC) treated with first line (1L) trastuzumab deruxtecan + pertuzumab (T-DXd + P) versus taxane + trastuzumab + pertuzumab (THP)

Romualdo Barroso-Sousa, Hospital Brasilia, Brasilia, Brazil

P3-14-25

Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): Updated results from the ongoing Beamion BCGC-1 phase Ib/II trial

Sara A Hurvitz, Fred Hutchinson Cancer Center, Seattle, WA

P3-14-26

Multisite Quality Improvement Workshops to Improve Adverse Event Monitoring and Supportive Care Delivery in HR+, HER2-Negative Metastatic Breast Cancer

Teresa van Oort, Association of Cancer Care Centers, Villa Park, IL

P3-14-27

Alpelisib plus trastuzumab (±fulvestrant) vs trastuzumab plus chemotherapy in HER2+/PIK3CA-mutated metastatic breast cancer: the ALPHABET randomized trial (GEICAM/2017-01_IBCSG 62-20_BIG 18-04)

Carmen Criscitiello, Humanitas University, Pieve Emanuele, Milan, Italy; Breast Medical Oncology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Oncology & Hematology (DIPO), University of Milan & Division, Milan, Italy

P3-14-28

Real-world progression-free survival and maintenance treatment patterns with first-line docetaxel, trastuzumab and pertuzumab in HER2+ metastatic breast cancer

Reshma L Mahtani, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P3-14-29

Tucatinib, Trastuzumab and Capecitabine with brain and/or spinal radiotherapy in patients with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer and leptomeningeal disease: a multi-centre phase II, single arm feasibility study ("CLIMB LMD"; NCT06016387).

Katarzyna Joanna Jerzak, University of Toronto, Toronto, ON, Canada

P3-14-30

Real-world efficacy and safety of T-DXd in metastatic breast cancer at a Comprehensive Cancer Center

Laia Casas, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain

P3-10-01

Genomic characterization of ER-Low breast cancer in the real-world flex registry: distinct biology and outcomes defined by the 70-Gene recurrence risk and the 80-gene molecular subtyping assays

Danilo Giffoni, London Health Sciences Centre, London, ON, Canada

P3-10-02

Publication of sentinel node omission clinical trials and variation in accrual and population on the NRG-BR007 phase III trial: De-escalation of Breast Radiation following breast-conserving surgery of stage 1, hormone-sensitive, HER2-, Oncotype Recurrence Score ≤18 breast cancer (DEBRA)

Julia R White, University of Kansas Medical Center Comprehensive Cancer Center, Kansas City, KS

P3-10-03

Initial endocrine therapy selection and outcomes among patients with hormone receptor-positive, HER2-negative early breast cancer: Analysis from the PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-03)

Michelle Li, Dana-Farber Cancer Institute, Boston, MA

P3-10-04

NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score ≤25 (OFSET)

Sandra Swain, Georgetown University Medical Center, Washington, DC

P3-10-05

Dissecting prognosis of patients with pN2-3 luminal A-like early breast cancer using a deep learning-based assay: a cohort study

Carmine Valenza, European Institute of Oncology, Milan, Italy

P3-10-06

Circulating Liquid biomarkers for Assessment and Identification of Recurrence in Early breast cancer: the CLAIRE Study

Kate A Dunsmore, Princess Margaret Cancer Centre, Toronto, ON, Canada

P3-10-07

Glp-1 receptor agonist use and endocrine therapy discontinuation rates among young women with early-stage hr+/her2- breast cancer

Mir Alishah, Endeavor Health, Evanston, IL

P3-10-08

Genomic high-risk distribution and associated clinicopathologic factors across three multigene assays in hormone receptor-positive, HER2-negative early breast cancer

Donghyeon Oh, Yeungnam University Medical Center, Daegu, Korea, Republic of

P3-10-09

Risk Stratification of T1N0 HR+ Breast Cancer Using the Breast Cancer Index: Results from the BCI Registry Study

Mark Pegram, Stanford University School of Medicine, Palo Alto, CA

P3-10-10

Associations of food access and race with high-risk OncotypeDX scores

Emily L Podany, Washington University in St. Louis, St. Louis, MO

P3-10-11

Health-related quality of life with adjuvant dalpiciclib plus endocrine therapy in patients with hormone receptor-positive, HER2-negative, early intermediate-to-high-risk breast cancer: Results from a multicenter, two-cohort phase 2 trial

Guiying Xu, Jilin Cancer Hospital, Changchun, China

P3-10-12

Low hormone receptor positive (HR+) breast cancer (BC) is biologically similar to triple negative breast cancer (TNBC): Molecular Features and Clinical Outcomes from the I-SPY2 Trial

Laura A Huppert, University of California San Francisco, San Francisco, CA

P3-10-13

Pre-surgical biopsy h&e enables early application of a validated ai risk model without loss of prognostic information

Gil Shamai, Technion – Israel Institute of Technology, Haifa, Israel

P3-10-14

Assessment of the adjusted Breast Cancer Index (BCI) model to estimate relative survival and relative mortality in postmenopausal, HR+, N0 breast cancer patients

Marie F. Jilderda, Leiden University Medical Center, Leiden, Netherlands

P3-10-15

Decision-making impact of the Breast Cancer Index in pre- versus postmenopausal women

Rena Callahan, UCLA Health, Valencia, CA

P3-10-16

Clinicopathological Stratification Reveals Prognostic Heterogeneity Within the INSEMA-like Population

Masanori Oshi, Yokohama City University Hospital, Yokohama, Japan

P3-10-17

Benefit of Extended Endocrine Therapy in BRCA1, BRCA2, CHEK2 and PALB2 Pathogenic Variant Carriers with ER+/HER2- Breast Cancer by Breast Cancer Index (BCI)

Siddhartha Yadav, Mayo Clinic, Rochester, MN

P3-10-18

Despite More Frequent Pathologic Tumor Upstaging, High-Volume Axillary Nodal Disease Remains Uncommon among Patients with Invasive Lobular Carcinoma Eligible for Sentinel Lymph Node Biopsy Omission

Anshulika Deshmukh, Duke University, Durham, NC

P3-10-19

Endocrine therapy (ET) resistance and recurrence site as prognostic factors for patients with HR-positive/HER2-negative locoregional recurrent (LRR) breast cancer (BC): a cohort study.

Nadia Bianco, European Institute of Oncology, IRCCS, Milan, Italy

P3-10-20

80-gene molecular subtyping assay informs neoadjuvant platinum-based treatment selection and predicts high pathologic complete response in hr+/her2− breast cancer

Joyce O'Shaughnessy, Baylor University Medical Center, Texas Oncology, Dallas, TX and Sarah Cannon Research Institute, Dallas, TX

P3-10-21

Validation of the ASTRRA-derived composite risk model for ovarian function suppression benefit in premenopausal hormone receptor-positive breast cancer

Dahn Byun, Samsung Medical Center, Seoul, Korea, Republic of

P3-10-22

Adjuvant systemic treatment patterns after sentinel lymph node biopsy omission in premenopausal patients with hormone receptor-positive and HER2-negative breast cancer in NAUTILUS trial

Eunhye Kang, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of

P3-10-23

Beyond clinicopathological Risk Stratification: Independent validation of a multi-omic biosignature for locoregional recurrence risk in a multi-institutional cohort in women aged 50 years or older with early-stage invasive breast cancer

Karuna Mittal, PreludeDx, Laguna Hills, CA

P3-10-24

Refining risk stratification in stage II or III HR-positive, HER2-negative early breast cancer: a national registry-based, streamlined clinicopathological model for the clinical "gray zone"

Jwo-Huey Yu, Taipei Veterans General Hospital, Taipei City, Taiwan

P3-10-25

Ovarian function suppression improves long-term breast cancer-free interval in chemotherapy-free premenopausal women aged 45 years or younger with hormone receptor-positive/HER2-negative early breast cancer and Recurrence Score 25 or less

Ayako Kurose, St. Luke's International Hospital, Tokyo, Japan

P3-10-26

Association of Obesity and Metabolic Syndrome with Response to Neoadjuvant Endocrine Therapy

Mary D Chamberlin, Geisel School of Medicine at Dartmouth, Hanover, NH

P3-10-27

A phase II study of palbociclib plus endocrine therapy in patients with clinically and genomically high-risk ER-positive/HER2-negative T1-2N0-1 early breast cancer incorporating the GenesWell™ BCT assay (HiPEX, KCSG BR19-13, NCT04247633)

Yeon Hee Park, Samsung Medical Center, Seoul, Korea, Republic of

P3-10-28

Intrinsic subtype distribution and evolution in patients with germline BRCA-associated HR-positive/HER2-negative breast cancer: the multicenter PAMBRACA study

Emma Zattarin, University of Modena and Reggio Emilia, Modena, Italy

P3-10-29

Prognostic utility of POTENT eligibility and Composite risk stratification in hormone receptor-positive, HER2-negative early breast cancer: A real-world pre-S-1 cohort study

Chihiro Toyoda, Nagoya University Hospital, Nagoya, Japan

P3-10-30

Early Recurrence After Adjuvant CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Clinical and Genomic Characterization

Shira Gabizon Peretz, Yale University, New Haven, CT

P3-11-01

Potential use of GLP-1 receptor agonists in combination with endocrine therapy for treating women with ER+ breast cancer

Eileen Li, University of Chicago, Chicago, IL

P3-11-02

Real-world clinical outcomes of neoadjuvant chemotherapy (NACT) in high-risk early-stage ER+/HER2−breast cancer: A US community practice study

Peter A Fasching, University Hospital Erlangen, Erlangen, Germany

P3-11-03

Incidence of venous thromboembolism in patients receiving adjuvant CDK4/6 inhibitors: a real-world single-center cohort study

Hosam Alghanmi, Princess Margaret Cancer Centre, Toronto, ON, Canada

P3-11-04

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS≤25 (RxFINE-Low): ECOG-ACRIN EA1242

Nancy Chan, Laura and Issac Perlmutter Cancer Center at NYU Langone, New York, NY

P3-11-5

Age-related overtreatment in early-stage hr+/her2− breast cancer: persistent use of mastectomy and association with worse survival

Joseph Zouein, Cooper University Health Care, Camden, NJ

P3-11-06

Strong APOBEC3A expression associates with poor prognosis for ER-positive/HER2-negative breast cancer patients

John WM Martens, Erasmus MC Cancer institute, Rotterdam, Netherlands

P3-11-7

Encapsulated Papillary Carcinoma of the Male Breast: Case Report and Systemic Literature Review

Roxana Soler, HCA Aventura Florida, Miami, FL

P3-11-08

Switching from Nonsteroidal to Steroidal Aromatase Inhibitors Reduces Menopausal Symptom Burden in Postmenopausal Breast Cancer Patients

Keri M Cronin, mt sinai west, New York, NY

P3-11-09

Artificial Intelligence-Enabled Risk Stratification in Invasive Lobular Breast Cancer

Albert Grinshpun, Shaare Zedek Medical Center, Jerusalem, Israel

P3-11-10

Potential impact of sentinel lymph node biopsy omission on adjuvant systemic treatment decisions in low-risk breast cancer patients

Asma Munir, Prince Philip Hospital, Llanelli, United Kingdom

P3-11-11

Lobular Histology Is Associated with Discordance Between Ki67 Proliferation Index and 21-Gene Recurrence Score: Evidence from a Real-World Cohort

Saeed Rafii, Mediclinic City Hospital, Dubai, United Arab Emirates

P3-11-12

Prognostic role of type and location of germline BRCA1 and BRCA2 variants in patients with HR+/HER2-negative early breast cancer

Bianca Malagutti, European Institute of Oncology IRCCS, Milano, Italy

P3-11-13

Anne trial: a phase 2 single-arm clinical trial to assess the feasibility and efficacy of neoadjuvant anastrozole in luminal breast cancer, stages II-III

Carlos Eduardo Paiva, Queen's University, Kingston, ON, Canada

P3-11-14

Germline BRCA2 Status Predicts Response to Neoadjuvant Chemotherapy in Patients With Hormone Receptor-Positive/HER2-Negative Breast Cancer

Letizia Matera, European Institute of Oncology, IRCCS, Milan, Italy

P3-11-15

Spatially-resolved profiling of chromatin accessibility in luminal a breast cancer

Ming-Wen Hu, Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA

P3-11-16

Lipidomic profiling in early-stage HR+/HER2− breast cancer during dual GLP-1/GIP agonist therapy in the FITWISE trial

Coral Omene, Rutgers Cancer Institute, New Brunswick, NJ

P3-11-18

Patterns of immunophenotypic conversion from primary HR-positive/HER2-negative breast cancer to recurrent disease and their impact on survival: A peruvian cohort

Zaida Morante, Instituto Nacional de Enfermedades Neoplásicas, Surquillo, Lima, Peru

P3-11-19

Real-world treatment patterns and clinical outcomes among patients with intermediate- and high-risk HR+/HER2- early breast cancer (eBC) receiving endocrine therapy (ET) with or without CDK4/6 inhibitors (CDK4/6i)

Meng Ru, AstraZeneca, Gaithersburg, MD

P3-11-20

Real-world adjuvant endocrine therapy treatment uptake among patients with hr+,her2− early breast cancer in 2015-2025

Michael Danso, Sarah Cannon Research Institute; Virginia Oncology Associates, Norfolk, VA

P3-11-21

Characteristics, treatment patterns, and survival outcomes among elderly patients with high-risk early-stage ER+/HER2− breast cancer: A SEER-Medicare analysis including a KEYNOTE-756-aligned subgroup

Jagadeswara R. Earla, Merck & Co., Inc., Rahway, NJ

P3-11-24

An ultra-rapid, fully automated 21-gene RT-PCR assay for decentralized recurrence risk testing: concordance with an established genomic risk score in early-stage breast cancer

Wolfgang Michael M Korn, Biocartis NV, Mechelen, Belgium

P3-11-25

Efficacy of oral multi-node PI3K/AKT/mTOR pathway inhibition by serabelisib and sapanisertib (PIKTOR) with next-generation breast cancer agents in preclinical models of HR+/HER2− breast cancer

Oliver D. K. Maddocks, Faeth Therapeutics, Cambridge, United Kingdom

P3-11-26

Distinct Age-Related Toxicity Profiles With Adjuvant Abemaciclib in Early Breast Cancer: Updated Results From the UK CONCISE Study

Olubukola Ayodele, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

P3-11-27

Real-world outcomes of neoadjuvant endocrine therapy for ER-positive early breast cancer: predictors of response and long-term safety

Arran K Turnbull, University of Edinburgh, Edinburgh, United Kingdom

P3-11-28

Association Between Tumor Grade and Oncotype DX Recurrence Score: A Real-World Analysis

Apostolos Zavos, General Hospital of Thessaly, Larissa, Greece

P3-11-29

Treatment decision agreement before and after OncotypeDX in early HR+/HER2- breast cancer: a single-center analysis

Filippo Sepe, AOU Luigi Vanvitelli, Naples, Italy

P3-11-30

The safety of CKD4/6 inhibitor ribociclib in the adjuvant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer treatment setting: real-world experience from a single centre

Tea Gaberc, University Hospital for Tumors, University Hospital Sestre Milosrdnice, Zagreb, Croatia

P3-12-01

Factors Associated With Adjuvant (Adj) Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) Treatment Utilization Among Patients (Pts) With Stage II/III HR+/HER2− Early Breast Cancer (EBC): A Retrospective US Real-World Study

Lasika Seneviratne, Los Angeles Cancer Network, Los Angeles, CA

P3-12-02

Real-world adjuvant CDK 4/6 inhibitor prescribing patterns for early-stage breast cancer: a multi-institution cohort study

Yuta Ishiyama, University of California San Francisco, San Francisco, CA

P3-12-03

Can PAM50 Genomic Risk Identify Patients Who Benefit from Anthracyclines? A Real-World Analysis in Early Breast Cancer

Camilla Capasso, Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain

P3-12-04

Real-world characteristics, treatment patterns and early outcomes of patients (pts) with HR+/HER2- early breast cancer (eBC) treated with adjuvant ribociclib: a single-center Spanish experience.

beatriz Alonso de castro, A Coruña University Hospital, A Coruña, Spain

P3-12-05

Real-world safety and tolerability of adjuvant abemaciclib: a single-center experience

Lea Ledinsky, University Hospital for Tumors, University Hospital Sestre Milosrdnice, Zagreb, Croatia

P3-12-06

Correlation Between Oncotype DX and Predict Recurrence Scores in Breast Cancer According to Nodal Status

Isabel Saffie, Fundacion Arturo Lopez Perez OECI Cancer Center, Santiago, Chile

P3-12-07

Online CME Drives Measurable Practice Change in Biology-Based Care for High-Risk HR+/HER2- Early Breast Cancer: A Claims-Based Outcomes Study

Urvi Patel, Medscape Oncology, Newark, TX

P3-12-08

Overall Survival and Treatment Patterns in Older Adults with Hormone Receptor Positive Invasive Ductal Versus Metaplastic Breast Cancer

Sara Golidy, University of Toledo, Toledo, OH

P3-12-09

Discovery and Independent Validation of NMF-Derived Spatial Recurrence Programs in Luminal Breast Cancer Reveal Concurrent Epithelial and TME Reprogramming in Histologically Normal Tissue

Delina Kambo*, University of California San Diego, La Jolla, CA

P3-12-10

Extended Adjuvant Endocrine Therapy Beyond 5 years Ovarian Function Suppresion in Pre-/Peri-menopausal High Risk ER+/HER2- Breast Cancer: Turkish Oncology Group (TOG) Study

Mutlu Dogan, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey

P3-12-11

Machine Learning Clinicopathologic Classifiers for Predicting High Recurrence Risk in Breast Cancer

Nikitha Vobugari, University of Minnesota, Minneapolis, MN

P3-12-12

Noela: a prospective phase II trial evaluating omission of adjuvant endocrine therapy in postmenopausal women with ultra-low-risk luminal A early breast cancer

José Luis Sandoval, Geneva University Hospitals, Genève, Switzerland

P3-12-13

Real-world effectiveness of individualized kampo medicine for endocrine therapy-related symptoms in breast cancer patients

Mutsuki Furukawa, University of Toyama, Toyama, Japan

P3-12-14

Correlation between clinicopathological risk factors and the 21-gene assay in hormone receptor-positive HER2-negative early-stage breast cancer patients

Ifrah Ahmad, Medical Service Center for Histology, Cytology and Molecular Pathology Trier GmbH, Trier, Germany, Trier, Germany

P3-12-15

Machine learning applied to liquid biopsy and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) for early prediction of response to neoadjuvant anastrozole: exploratory results from the ANNE trial

Carlos Eduardo Paiva, Queen's University, Kingston, ON, Canada

P3-12-16

Feasibility, Safety, and Long-Term Outcomes of Iterative Locoregional Treatment for Patients with Second Consecutive Ipsilateral Breast Cancer Locoregional Recurrences

Letizia Matera, European Institute of Oncology, IRCCS, Milan, Italy

P3-12-17

Effect of Ovarian Function Suppression (OFS) on Disease Free Survival (DFS) in Premenopausal Women with Hormone Receptor Positive HER-2 Positive Early-Stage Breast Cancer who Achieve Pathologic Complete Response (pCR) to Neoadjuvant Therapy: A Real-World Retrospective Study

Olivia Vizzini, Emory University School of Medicine, Atlanta, GA

P3-12-18

Societal Impact of Adjuvant Giredestrant in HR+, HER2− Early Breast Cancer: A Treatment Impact Model Based on the Phase III lidERA Breast Cancer Trial

Emma Behan, Genentech Inc., South San Francisco, CA

P3-12-19

Fda/ema criteria identify candidates for adjuvant abemaciclib but fail to capture all patients at high risk of distant relapse after neoadjuvant chemotherapy

Maxime BRUNET, Institut Bergonié, Bordeaux, France

P3-12-20

Blood group B is associated with visceral, particularly liver, metastatic recurrence in luminal breast cancer with limited nodal involvement

Koji Tezuka, Hoshi General Hospital, Koriyama, Japan

P3-12-21

Development and Internal Validation of the Lleida Oncotype Predictor (LOP): A Clinicopathological Model to Predict High Oncotype DX® Recurrence Score in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer

Serafin Morales, Hospital Arnau de Vilanova de Lleida, ALPICAT, Spain

P3-12-22

Residual Cancer Burden (RCB) score is significantly associated with outcome following Neoadjuvant Endocrine Therapy Treatment in Early ER+ Breast Cancer

Arran K Turnbull, University of Edinburgh, Edinburgh, United Kingdom

P3-12-23

Prediction of “higher late than early recurrence” in hormone receptor positive breast cancer using Breast cancer index assay and Oncotype Dx assay

Umida Khakimova, Maimonides Medical Center, Brooklyn, NY

P3-12-24

Genomic landscape and prognostic impact of PIK3CA mutations in high-risk early-stage HR+ and HER2- breast cancer among Chinese patients

Zhi Xiao, Xiangya Hospital, Central South University, Changsha, China

P3-12-25

Clinical Risk Poorly Reflects Genomic Riskin ER-Positive/HER2-Negative Early Breast Cancer: The 21-Gene Recurrence Score Reflects Progesterone Receptor Expression and Grade More Than Anatomic Burden

Elif Senocak Tasçi, Acıbadem MAA University, Istanbul, Turkey

P3-12-6

Randomized window of opportunity trial evaluating zotatifin in estrogen receptor-positive, HER2-negative breast cancer: the phase 2 TERPSICHORE trial

Jennifer Caswell-Jin, Stanford University School of Medicine, Stanford, CA

P3-12-27

Early Oncologic Outcomes of Targeted Axillary Dissection Versus Axillary Lymph Node Dissection in Biopsy-Proven HR+/HER2− Node-Positive cT1/T2 Breast Cancer

Mutlu Dogan, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey

P3-12-28

Development and validation of a Nomogram for predicting axillary lymph node metastasis in patients with early-stage Luminal breast cancer: A study in Vietnam

Nguyen Xuan Dai, Hanoi Medical University, Hanoi, Viet Nam

P3-12-29

Contralateral Prophylactic Mastectomy in Early-Stage HR+/HER2− Breast Cancer: Age-Dependent Survival Associations in a National Cohort

Joseph Zouein, Cooper University Health Care, Camden, NJ

P3-12-30

Occult nodal disease in cN0 patients with HR+HER2- early breast cancer; implications for omission of sentinel lymph node biopsy in a Latin American cohort

Javier Emanuel Reyes-Díaz, National Cancer Institute Of Mexico, Mexico City, Mexico

P3-13-01

Adjuvant Use of CDK 4/6 inhibitor Treatment for High-Risk Hormone Receptor-Positive Early Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Immunotherapy through I-SPY

Alyssa Pama, University of California San Francisco, San Francisco, CA

P3-13-02

Esr1 mrna expression and a multi-gene predictive model for response to neoadjuvant chemotherapy in er positive/her2 negative breast cancer

Vivian Vasconcelos, State University of Campinas (UNICAMP), Campinas, Brazil

P3-13-03

Utility of Local Tumor Destruction and Hormone Therapy for the Management of Ductal, Lobular, and Mixed Histology Hormone Receptor Positive, HER2 negative Breast Cancer (HR+/HER2- BC)

Kenna Noel Koehler, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

P3-13-05

Receptor switching, treatment & outcomes of ER+/HER2- early breast cancer patients relapsing during or following cyclin-dependent 4/6 inhibitor therapy

Conor Taylor, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom

P3-13-06

False Elevation of Estradiol During Abemaciclib Therapy in Premenopausal Women Receiving Ovarian Function Suppression: A Single-Institution Case Series

James O'Bryan, Medical University of South Carolina, Charleston, SC

P3-13-08

Treatment Patterns and Clinical Profiles in HR+/HER2− Early Breast Cancer Following Ribociclib US FDA Approval: A Real-World Analysis

Vikram Gorantla, Oncology and Hematology Associates, University of Pittsburgh, Pittsburg, PA

P3-13-09

Mammaprint magee equation: a regression equation to predict mammaprint score using histopathologic variables

Rohit Bhargava, University of Pittsburgh, UPMC Magee-Womens Hospital, Pittsburgh, PA

P3-13-10

Real-world study of adjuvant abemaciclib dose management in high-risk breast cancer (Esea study)

Francisco Ayala de Peña, H. G.U. Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), U. Complutense, Madrid, Spain., Madrid, Spain

P3-13-11

Real-world impact of neoadjuvant immunotherapy in localized hormone-positive breast cancer: a single institution review of responses, surgical outcomes, and equity across a diverse population

Ratika Dogra, Henry ford Health, Detroit, MI

P3-13-12

Utilization of Adjuvant Ribociclib in Eligible Patients with HR+/HER2- Stage II/III Early Breast Cancer (eBC)

Niharika Duggirala, David Geffen School of Medicine at UCLA, Los Angeles, CA

P3-13-13

Prevalence of trop-2 overexpression in early and locally advanced hormone receptor-positive/her2-negative breast cancer treated with neoadjuvant systemic therapy: a mexican national cancer institute cohort

Emy Estefany Garcia Guillen, Instituto Nacional de Cancerologia, CDMX, Mexico

P3-13-14

Two-year trend analysis: online cme sustains and scales real-world adoption of biology-based therapy in oncologists treating hr+/her2- early breast cancer

Urvi Patel, Medscape Oncology, Newark, NJ

P3-15-01

Clinical Outcomes After Metastatic Recurrence Following KEYNOTE-522 in a Real-World Triple-Negative Breast Cancer (TNBC) Cohort

Yao Yao, UT Southwestern Medical Center, Dallas, TX

P3-15-02

First-in-human dosimetry of CLR 125, an auger electron-emitting lipid-raft-targeted phospholipid radioconjugate, in relapsed triple-negative breast cancer: initial results from an ongoing phase 1b study

Jarrod Longcor, Cellectar Biosciences, Florham Park, NJ

P3-15-03

Digital Pathology (DP) Biomarker Analysis of Trophoblast Cell Surface Antigen-2 (Trop-2) in Participants (pts) With Advanced Programmed Death-(Ligand) 1 (PD-[L]1) Inhibitor Ineligible Triple-Negative Breast Cancer (TNBC) From the Randomized Phase 3 ASCENT-03 Trial

Sara Hurvitz, Clinical Research Division, Fred Hutchinson Cancer Center, UW Medicine, Seattle, WA

P3-15-04

Survival by Metastatic Site in Triple-Negative Breast Cancer Treated With Immunotherapy: Real-World Analysis

Michael Schwartz, Winship Cancer Institute of Emory University, Atlanta, GA

P3-15-05

Evaluating Spatial Tumor Architecture as a Candidate Prognostic Biomarker in Triple-Negative Breast Cancer Using Semantic Segmentation

Himangi Srivastava, Memorial Sloan Kettering Cancer Center, New York, NY

P3-15-06

Real-world non-treatment and attrition rates in advanced triple-negative breast cancer

Wesley Antônio Lopes de Lima, Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil

P3-15-07

Metabolic reprogramming by L024 for the prevention and interception of triple-negative breast cancer metastasis to the brain

Caroline Hitsman, Kenyon College, Gambier, OH

P3-15-08

Olaparib and Durvalumab for the Treatment of Metastatic Triple Negative Breast Cancer: The AMTEC Trial

Zahi Mitri, BC Cancer Vacouver, Vancouver, BC, Canada

P3-15-09

Triple-negative breast cancer in bangladesh: a real-world snapshot of disease burden and the hidden brca1/2 testing gap

Qamruzzaman Chowdhury, Bangladesh Specialized Hospital, Dhaka, Bangladesh

P3-15-10

Loss of Arginase 2 Promotes Lung Metastasis in Immunocompetent Hosts via Nitric Oxide Synthase 2-Dependent Th17 Response

Shu-Ting Chou, Vanderbilt University, Nashville, TN

P3-15-11

Beta-blocker use and outcomes in advanced tnbc treated with chemo-immunotherapy: an exploratory analysis of the impassion130 trial

Gonzalo D Spera, Translational Research in Oncology, Montevideo, Uruguay

P3-15-12

Ndrg1-mediated membrane phospholipid remodeling drives AKT activation and aggressiveness in inflammatory breast cancer

Kiros Haddish Tesfamariam, MD Anderson Cancer Center, Houston, TX

P3-15-13

Timing of recurrence after KEYNOTE-522 and eligibility for first-line anti-Trop2 antibody-drug conjugate (ADC) in patients with triple-negative breast cancer (TNBC): a cohort study

Bianca Malagutti, European Institute of Oncology, IRCCS, Milano, Italy

P3-15-14

Serial Monitoring of Circulating Epithelial Tumor Cells Is Associated with Response to Pembrolizumab and Relapse-Free Survival in Early Triple-Negative Breast Cancer

Dorothea Schott, Laboratory Dr. Pachmann, Bayreuth, Germany

P3-15-15

Real-world clinical outcomes of sacituzumab tirumotecan in metastatic triple-negative breast cancer: a retrospective study

Huihui Li, Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences., Jinan, Shandong Province, China, China

P3-15-16

Outcomes in De Novo Stage IV triple negative inflammatory breast cancer treated with trimodality therapy

Azadeh Nasrazadani, MD Anderson Cancer Center, Houston, TX

P3-15-17

Digital Pathology (DP) Biomarker Analysis of Trophoblast Cell Surface Antigen-2 (Trop-2) in Participants (pts) With Advanced Programmed Death-Ligand 1 (PD-L1)+ Triple-Negative Breast Cancer (TNBC) From the Randomized Phase 3 ASCENT-04/KEYNOTE D19 Study

Peter Schmid, Centre for Experimental Cancer Medicine, Bart’s Cancer Institute, Queen Mary University of London, London, United Kingdom

P3-15-18

Real-world treatment patterns and outcomes in patients (pts) with human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer with high relapse risk after standard neoadjuvant treatment

Frederik Marmé, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

P3-15-19

Body Mass Index and Toxicity-Related Dose Modifications in patients with Metastatic Breast Cancer treated with Sacituzumab Govitecan

Marianna Sirico, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST IRCCS, Meldola, Italy

P3-15-20

Documented metformin exposure at pembrolizumab initiation as an immunometabolic covariate in PD-L1-positive metastatic triple-negative breast cancer: an exploratory CEBCC-101 subanalysis

Aleksandra Konieczna, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, Warszawa, Poland

P3-15-21

Real-world overall survival with first-line sacituzumab govitecan versus paclitaxel in PD-L1-negative triple-negative breast cancer with brain metastases at diagnosis

Zunairah Shah, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P3-15-22

A Prospective Observational Study of Atezolizumab plus Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer: Final Analysis of JBCRG-C08/ATTRIBUTE

Nobuhiro Shibata, Kansai Medical University Hospital, Hirakata, Japan

P3-15-23

Mtap loss in advanced triple negative breast cancer (TNBC)

Nicole Casasanta, Yale Cancer Center, Yale School of Medicine, New Haven, CT

P3-15-24

Patient-reported experiences, symptom burden, and unmet supportive care needs among adults with metastatic triple-negative breast cancer: first national U.S. survey

Victoria Barghout, Viver Health LLC, Morristown, NJ

P3-15-25

Sabina: a phase ii trial of men1611 plus eribulin in pik3ca/pten-altered advanced metaplastic breast cancer

Antonio Llombart-Cussac, Hospital Arnau de Vilanova; Medica Scientia Innovation Research (MedSIR), Valencia, Spain

P3-15-26

Beyond CREATE-X: A Global Meta-Analysis of Adjuvant Capecitabine in Residual Triple-Negative Breast Cancer.

Kesar Prajapati, Metropolitan Hospital Center, EDGEWATER, NJ

P3-15-27

Blood-based Circulatory Cancer Cell Biology in Metastatic Triple Negative Breast Cancer Patients from SWOG1416 Trial

Ian Ward, University of Southern California, Los Angeles, CA

P3-15-28

Identifying Patients With Triple-Negative Breast Cancer and Brain Metastases for Future Clinical Trials: Prognostic Factors From the BMBC Registry

Volkmar Mueller, University Medical Center Hamburg- Eppendorf, Hamburg, Germany

P3-15-29

Association of baseline statin use with outcomes of first-line pembrolizumab plus chemotherapy in PD-L1-positive metastatic triple-negative breast cancer

Aleksandra Konieczna, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

P3-15-30

Translational development of PCT1:CO‑STIM, an ICOS‑enhanced TCR‑engineered T‑cell therapy targeting ROPN1, supports clinical evaluation inadvancedtriple‑negative breast cancer

Marte C Liefaard, Pan Cancer T, Rotterdam, Netherlands

P3-9-22

6-month mobile support intervention reduced inflammatory gene expression in young breast cancer survivors

Kristen D Brantley, Dana-Farber Cancer Institute, Boston, MA

P3-3-13

Contextual Bias in AI Emotion Recognition: How Clinical Narratives Alter AI Perception in a Simulated Breast Surgery Post-Operative Visit

Claire Dvorak, Orlando Health, Orlando, FL

P3-3-18

Accuracy and Precision of Radio-Wave Breast Density Quantification as an Alternative to Mammographic Assessment

Nisha Sharma, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

P3-3-19

Clinicopathologic Characteristics of Breast Cancer Patients Harboring High-Penetrance Non-BRCA Germline Mutations: A Comparison with BRCA1/2 Carriers in a Cohort of More than 8,000 Patients

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P3-3-20

Use of the canrisk tool to estimate pathogenic variant probability in high-risk brazilian breast cancer outpatients populations in public health service

Cesar Cabello, State University of campinas – UNICAMP, campinas, Brazil